Details

Autor(en) / Beteiligte

• Hortobagyi, Gabriel N
• Theriault, Richard L
• Porter, Lester
• Blayney, Douglas
• Lipton, Allan
• Sinoff, Clive
• Wheeler, Helen
• Simeone, Joseph F
• Seaman, John
• Knight, Robert D
• Heffernan, Maika
• Reitsma, Dirk J
• Kennedy, Ian
• Allan, Simon G
• Mellars, Kathleen

Titel

Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

Ist Teil von

• The New England journal of medicine, 1996-12, Vol.335 (24), p.1785-1792

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

1996

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Bone metastases occur in most women with advanced breast cancer. The destruction of bone in these lesions results from osteoclast-induced bone resorption that may be stimulated by osteoclast-activating factors released by tumor cells. 1 , 2 Cytotoxic chemotherapy or hormone therapy is the preferred treatment for symptomatic bone disease, but progressive skeletal destruction ultimately leads to increased pain, immobility, and deterioration in the quality of life. Bisphosphonates are potent inhibitors of osteoclastic bone resorption and are effective in treating cancer-related hypercalcemia. 3 , 4 Pamidronate disodium, a second-generation bisphosphonate, inhibits the resorption of bone at doses that do not affect bone mineralization. 5 The results . . .